About Conference
Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Dementia, is one of the biggest global public health challenges facing our generation. Worldwide, at least 44 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 115 million. In 2011, an estimated 747,000 Canadians were living with Alzheimer’s or other dementias by 2031, it is estimated that 1.4 million Canadians will have dementia. In Canada 72% of Alzheimer's sufferers are women and 62% of dementia cases are also women. Much of the increase will be in developing countries like Western Europe and North America.
Already 62% of people with dementia live in developing countries. Today, over 35 million people worldwide currently live with the condition. This number is expected to double by 2030 and more than triple by 2050 to 115 million.
No treatments available to slow or stop the brain damage caused by Alzheimer’s disease, several medications can temporarily help improve the symptoms of dementia for some people. In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost $300 billion per year. Globally, dementia cost $600 billion a year.
None of the pharmacologic treatments (medications) available today for Alzheimer’s disease slows or stops the damage and destruction of neurons that cause Alzheimer’s symptoms and make the disease fatal. The six drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s temporarily improve symptoms by increasing the amount of chemicals called neurotransmitters in the brain.A1 The effectiveness of these drugs varies from person to person.
Welcome message
Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums every year on Pharma, Medicine, Science and Technology
Here we welcome you to the 10th World Congress on Dementia during May 25-26, 2018 in the city of New York, USA.
Dementia 2018 mainly focusing on Alzheimer’s disease, Dementia, Imaging Techniques associated with Biomarkers, Various Animal models, Geriatrics and Cognitive Disorder, Pathophysiology, Care practice and Awareness, Current Trends and Awareness in Dementia and Alzheimer’s Disease.
Dementia is generally caused due to alterations in the structure of brain. Based on the recent statistical data more than 5 million Americans are living with dementia and the number is expected to rise up to 16 million by 2050. It’s very pathetic that for every 66 seconds someone in America are developing Dementia and related diseases and 1 in 3 die daily with the
Alzheimer's or Dementia. Since 2000, death records of the heart respective diseases were decreased by 14% and drastically the deaths of Dementia related diseases increased to 89%
Alzheimer's or Dementia. Since 2000, death records of the heart respective diseases were decreased by 14% and drastically the deaths of Dementia related diseases increased to 89%
Why to Attend?
Conduct demonstrations, workshops, and symposiums, distribute information, meet with potential national & international delegates, professors and explore with a new product line, and receive recognition at this 2-day event. World-renowned speakers, the most recent researches, innovations, and the Novel updates in Dementia field are hallmarks of this congress.
Target Audience
Directors, Neurologist, Neurosurgeons, Psychiatrist, Surgeon, Head of department, Industries, Business delegates, Clinicians, Community Members, Professors and Students from Academia in the research of Dementia and related disorders
